Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on PTC Therapeutics (NASDAQ:PTCT) and raises the price target from $62 to $64.
August 09, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska maintains an Overweight rating on PTC Therapeutics and raises the price target from $62 to $64.
The Overweight rating and increased price target from a reputable analyst at Cantor Fitzgerald is likely to positively influence investor sentiment and drive short-term price appreciation for PTCT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100